Dandekar Atul 4

What Happened

• Atul Dandekar, Chief Strategy & Business Officer (CSBO) of Maze Therapeutics, exercised 7,500 stock options at $10.42 per share (cost = $78,150) on January 29, 2026 and sold a total of 7,500 shares the same day for aggregate proceeds of $331,990.
• The sale breaks down as: 1,200 shares at a weighted avg $43.18 ($51,821), 3,500 shares at a weighted avg $44.04 ($154,147), and 2,800 shares at a weighted avg $45.01 ($126,022). The Form 4 also reports a separate derivative/conversion entry for 7,500 shares at $0.00 (see footnotes).

Key Details

• Transaction date: January 29, 2026; Form 4 filed February 2, 2026 (timely filing).
• Exercise: 7,500 shares exercised at $10.42 each (total cost $78,150).
• Sales: 7,500 shares sold for total proceeds ~$331,990; reported as weighted averages with price ranges:
  • 1,200 shares sold at $42.49–$43.46 (weighted avg $43.18) (F2)
  • 3,500 shares sold at $43.51–$44.49 (weighted avg $44.04) (F3)
  • 2,800 shares sold at $44.54–$45.53 (weighted avg $45.01) (F4)
• Shares owned after the transactions are not specified in the provided excerpt.
• Notable footnotes:
  • F1: Sales effected under a Rule 10b5‑1 trading plan adopted Sept 29, 2025.
  • F5: The option exercised was fully vested as of March 17, 2025.
• No indication this Form 4 was late (filed within required reporting window).

Context

• This pattern—exercise of vested options and same‑day sale of an equal number of shares—is commonly used to cover option exercise costs and taxes (often described as a cashless or simultaneous sale), and here the sale activity was executed under a pre-established 10b5‑1 plan.
• The filing is factual and does not by itself indicate the insider’s view on the company; purchases typically carry stronger signals than routine option exercises followed by sales.